Circular RNA circSMARCA5 is a prognostic biomarker in patients with malignant tumor: a meta-analysis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2001-
    • Subject Terms:
    • Abstract:
      Background: Malignant tumor is one of the most serious diseases endangering human health. Circular RNAs play an important role in the tumorigenesis and progression of various malignant tumors. Although various studies have investigated the biological function of circular RNA circSMARCA5 in malignant tumors, the prognostic value of circSMARCA5 in malignant tumor patients has not been systematically analyzed.
      Methods: Relevant studies were obtained from the PubMed and Web of Science database. The quality of the enrolled studies was evaluated using the Newcastle-Ottawa Scale quality assessment system. Survival features and clinicopathological features were assessed using pooled hazard ratios and odds ratios with 95% confidence intervals, respectively.
      Results: Overall, 7 relevant publications were enrolled in the meta-analysis. CircSMARCA5 expression was significantly correlated with better OS (HR = 0.51, 95%CI 0.41-0.65) or DFS/RFS/PFS (HR = 0.56, 95%CI 0.43-0.73) in malignant tumors. In the pooled analyses of clinicopathological characteristics, malignant tumors with higher circSMARCA5 were better differentiated (OR = 0.41, 95%CI 0.19-0.88). CircSMARCA5 expression was correlated with less advanced TNM stage (OR = 0.33, 95%CI 0.19-0.55). Moreover, malignant tumors with higher circSMARCA5 expression have less advanced lymph node metastasis (OR = 0.26, 95%CI 0.08-0.79).
      Conclusion: These results indicated that circSMARCA5 was a promising biomarker in malignant tumors, which may potentially facilitate clinical decisions in the future.
    • References:
      RNA. 2014 Nov;20(11):1666-70. (PMID: 25234927)
      Eur J Epidemiol. 2010 Sep;25(9):603-5. (PMID: 20652370)
      Int J Mol Med. 2020 Jun;45(6):1697-1710. (PMID: 32236616)
      Cancers (Basel). 2019 Feb 07;11(2):. (PMID: 30736462)
      CA Cancer J Clin. 2021 Jan;71(1):7-33. (PMID: 33433946)
      J Hepatol. 2018 Jun;68(6):1214-1227. (PMID: 29378234)
      Cancer Res. 2020 Jun 1;80(11):2138-2149. (PMID: 32217695)
      BMC Cancer. 2019 Oct 10;19(1):937. (PMID: 31601173)
      Mol Cancer. 2020 Aug 24;19(1):128. (PMID: 32838810)
      Stat Med. 2002 Jun 15;21(11):1539-58. (PMID: 12111919)
      Biomed Res Int. 2020 Jan 22;2020:1487609. (PMID: 32090067)
      Mol Cancer. 2020 May 4;19(1):82. (PMID: 32366257)
      Trials. 2007 Jun 07;8:16. (PMID: 17555582)
      Biochem Biophys Res Commun. 2017 Nov 25;493(3):1217-1223. (PMID: 28765045)
      BMC Cancer. 2020 May 19;20(1):448. (PMID: 32429931)
      Hepatology. 2021 Apr;73(4):1419-1435. (PMID: 32750152)
      J Clin Lab Anal. 2020 Apr;34(4):e23138. (PMID: 31880360)
      J Cell Mol Med. 2020 Sep;24(17):9507-9517. (PMID: 32783378)
      J Cancer. 2020 Apr 27;11(14):4230-4239. (PMID: 32368306)
      Cancer Biol Med. 2015 Mar;12(1):10-22. (PMID: 25859407)
      Nucleic Acids Res. 2019 Jun 4;47(10):5325-5340. (PMID: 30937446)
      Mol Cancer. 2020 Jan 28;19(1):17. (PMID: 31992303)
      Cancer Cell. 2020 Jan 13;37(1):55-70.e15. (PMID: 31935372)
      Mol Cancer. 2019 Aug 30;18(1):131. (PMID: 31470874)
      Cell. 2019 Feb 7;176(4):869-881.e13. (PMID: 30735636)
      Dis Markers. 2019 Mar 6;2019:2473652. (PMID: 30956729)
      J Clin Lab Anal. 2020 May;34(5):e23195. (PMID: 31944395)
      Bio Protoc. 2018 Mar 20;8(6):. (PMID: 29644261)
      BMC Med. 2021 Feb 1;19(1):28. (PMID: 33517886)
      Dig Liver Dis. 2020 Dec;52(12):1494-1502. (PMID: 32807692)
      Mol Cancer. 2020 Jun 27;19(1):110. (PMID: 32593303)
      Sci Rep. 2015 Jan 27;5:8057. (PMID: 25624062)
      Nat Rev Mol Cell Biol. 2020 Aug;21(8):475-490. (PMID: 32366901)
      Nat Rev Cancer. 2019 Mar;19(3):123-124. (PMID: 30683893)
      Nat Biotechnol. 2014 May;32(5):453-61. (PMID: 24811520)
      Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):2449-2464. (PMID: 31198063)
      Proc Natl Acad Sci U S A. 1976 Nov;73(11):3852-6. (PMID: 1069269)
      Cancer Gene Ther. 2021 Jan 29;:. (PMID: 33514881)
    • Grant Information:
      18ZR1405800 National Science Foundation of Shanghai; JSZK2019A03 Project for Key Medical Specialty Construction in Jinshan District (6th Period, Type A)
    • Contributed Indexing:
      Keywords: Biomarker; Circular RNA; Malignant tumor; circSMARCA5
    • Accession Number:
      0 (Biomarkers, Tumor)
      0 (RNA, Circular)
    • Publication Date:
      Date Created: 20210526 Date Completed: 20211018 Latest Revision: 20211018
    • Publication Date:
      20240105
    • Accession Number:
      PMC8145840
    • Accession Number:
      10.1186/s12885-021-08316-3
    • Accession Number:
      34034688